vs 0.1) respectively. Conclusion: We were able to conclude that those patients with NSCLC who had TILi and TILSs, and who also had expression of PD-L1 in their tumor samples, had higher OS than those patients who did not have TILS or expression of PD-L1. This was statistically Hospital da Luz Lisboa, Lisboa/PT, 2 Hospital da Luz Lisboa, Lisboa/PT Background: A solitary pulmonary nodule (SPN) is a common and increasing clinical problem. Differential diagnosis is broad and often challenging, mainly in patients with previous cancer. Aim: Analyze patients with SPN and previous cancer and compare metastatic and primary lung cancer (PLC) lesions. Method: Patients with SPN on computerized tomography scan and history of cancer (except basal cell carcinoma) who underwent surgical resections between January 2015 and December 2017 at Hospital da LuzeLisboa were included. All cases were evaluated at a multidisciplinary lung cancer tumor board team meeting. We analyzed histology, demographic and radiological features. p-values 0.05 were considered significant. Results: There were included 29 patients with history of cancer: 12 colorectal, 8 breast, 4 genitourinary, 4 lung and 1 sarcoma. PLC was diagnosed in 15 (51.7%), metastasis in 11(37.9%)-8 colorectal, 1 genitorectal, 1 atypical lung carcinoid and 1 sarcoma -and benign lesions in 3. Surgery was the diagnosis procedure in 24(82.8%)e17 with frozen section. There were no significant differences between primary and metastatic neoplastic lesions in gender, age and smoking history (p>0.05). All subsolid nodules (n¼5) were PLC. In solid neoplastic SPN, 10 PLC and 11 metastasis, there was no difference in diameters. Irregular edge was associated with PLC lesions (p¼0.008) and smooth margin with metastasis (p¼0.001). Lobulated margins did not seem differentiate neoplastic lesions (p¼1.0). Conclusion: PLC is an important diagnosis in the differential diagnosis of NPS, including in patients with a history of cancer. Radiological features can help to discern primary to metastatic SPN in this group.
Background: A solitary pulmonary nodule (SPN) is a common and increasing clinical problem. Differential diagnosis is broad and often challenging, mainly in patients with previous cancer. Aim: Analyze patients with SPN and previous cancer and compare metastatic and primary lung cancer (PLC) lesions. Method: Patients with SPN on computerized tomography scan and history of cancer (except basal cell carcinoma) who underwent surgical resections between January 2015 and December 2017 at Hospital da LuzeLisboa were included. All cases were evaluated at a multidisciplinary lung cancer tumor board team meeting. We analyzed histology, demographic and radiological features. p-values 0.05 were considered significant. Results: There were included 29 patients with history of cancer: 12 colorectal, 8 breast, 4 genitourinary, 4 lung and 1 sarcoma. PLC was diagnosed in 15 (51.7%), metastasis in 11(37.9%)-8 colorectal, 1 genitorectal, 1 atypical lung carcinoid and 1 sarcoma -and benign lesions in 3. Surgery was the diagnosis procedure in 24(82.8%)e17 with frozen section. There were no significant differences between primary and metastatic neoplastic lesions in gender, age and smoking history (p>0.05). All subsolid nodules (n¼5) were PLC. In solid neoplastic SPN, 10 PLC and 11 metastasis, there was no difference in diameters. Irregular edge was associated with PLC lesions (p¼0.008) and smooth margin with metastasis (p¼0.001). Lobulated margins did not seem differentiate neoplastic lesions (p¼1.0). Background: Lung cancer is the one of the most common cancer in the elderly, advanced disease among older people has still worse outcomes and represents a challenge for the management. The aim of study was to evaluate the prognosis of elderly patients with metastatic lung cancer in a population of affiliates to a private institution (ONCOSA-LUD-AUNA). Method: In a retrospective study, we reviewed prognostic factors of patients diagnosed of metastatic lung cancer older than 60 years whom received treatment in our institution (ONCOSALUD-AUNA) between 2011-2014. Clinical characteristics, treatment and survival were evaluated from electronic medical records. Overall survival (OS) was estimated using the Kaplan-Meier method and comparisons of survival curves were performed using the Log-rank or Breslow test. Multivariate analysis was performed using Cox model. Results: In the study period, 92 cases older than 60 years were diagnosed. Median Age was 70 years (range: 61, 86), 44% were women, 35% had 2-4 ECOG scale, 58.6% had primary tumor in the right lung and the most common site of metastasis were brain, bone, pleura and liver. 65% were adenocarcinoma and 40% poorly differentiated. About 20% of cases did not received any treatment. The chemotherapy regimen was based on carboplatin and cisplatin, 82% received more than 3 cycles of chemotherapy and overall response rate was 44%. In 5 years median follow-up, 81% died, median survival was 0.9 years (CI95%: 0.6, 1.2), 2-and 5-years survival were 24 and 13%, respectively. OS showed differences according to ECOG (0-1 vs. 2-4, p¼0.008), primary site (right vs left, p ¼ 0.060), histology (adenocarcinoma vs non-adenocarcinoma, p ¼ 0.090), CYFRA 21.2 (<3.3 vs. >3.3, p ¼ 0.017), neutrophil-to-lymphocyte ratio (NLR) (3.6 vs. 3.6, p ¼ 0.001). In a Cox model, CYFRA 21.2 > 3.3 (HR: 2.2, p¼0.036), NLR > 3.6 (HR:2.8, p¼0.001) and histology (non-adenocarcinoma, HR:2.7, p¼0.01) were associated to worse survival outcomes. Conclusion: Lung cancer among elderly still has the worse prognosis, however patients with 0-1 ECOG scale, adenocarcinoma, CYFRA 21.2 < 3.3 and NLR < 3.6 were associated to better survival outcomes.
Conclusion

P46
Experience in the Treatment of 13 Cases of Pulmonary Lymphangitic Carcinomatosis with Apatinib P. Yang Thoracic Surgery, Tianjin First Central Hospital, Tian Jin/CN Background: Pulmonary lymphangitic carcinomatosis is a disease in which advanced malignant tumors spreads diffuse throughout the lungs along lymphatic vessels. The previous treatment methods of PLC have no special curative effect except standard chemotherapy and symptomatic support. This paper retrospectively analyzed 13 patients with advanced lung cancer of PLC treated by apatinib in our hospital in 2017, whose clinical symptoms and therapeutic effects are as follows:
Method: To summarize and analyze 13 cases of pulmonary lymphangitic carcinomatosis of my department , and evaluate the therapeutic effect of apatinib on pulmonary lymphangitic carcinomatosis, for the effective treatment of pulmonary lymphangitic carcinomatosis. 13 cases of pulmonary lymphangitic carcinomatosis treated by our department from June 2017 to June 2018 were retrospectively analyzed, all patients were treated with apatinib orally at a daily dose of 425 mg for 6 consecutive weeks. Its therapeutic effect was summarized and analyzed , and the progression-free survival period (PFS) and overall survival rate (OS) were followed up. CT imaging findings before and after the treatment was the main index, supplemented by tumor markers (CEA, CA -125, CYFRA21-1), analysis of blood gas, the change of clinical symptom index, etc for the analysis of adverse drug reactions. Results: The efficacy of 13 patients with pulmonary lymphangitic carcinomatosis was evaluated. Classification of the therapeutic effect included 6 patients (46.1%) of partially relieved (PR),3 patients (23.0%) of stable disease (SD),4 patients (30.7%) of progressive disease (PD). Objective response rate (CR+PR) was 46.1%. Disease control rate DCR(CR+PR+SD) was 69.2%. Progression-free survival (PFS) was 5.2 months. Overall survival OS was 10.2 months. The CT imaging features of part patients before and after treatment improved markedly, the differences of tumor markers CEA, ca-125, cyfra21-1 and blood gas analysis were statistically significant (P<0.05), Pleural effusion, dyspnea and other clinical symptoms have different degrees of relief. Adverse events were mainly high blood pressure (3/13), rash (4/13), hand-foot syndrome (6/13), mild proteinuria (2/13), and All are tolerable. Conclusion: Pulmonary lymphangitic carcinomatosis is a disease of lymphatic spread in the advanced malignant tumors, Apatinib not only has good curative effect, but also brings obvious survival benefits, and the incidence of adverse reactions is low and the patient is well tolerated. Apatinib has become the main treatment of PLC compared to the traditional treatment. Keywords: apatinib, Diagnosis, Therapy, pulmonary lymphangitic carcinomatosis
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